The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
Eur Urol Oncol
; 7(3): 313-315, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38485615
ABSTRACT
Recent findings reported for the phase 3 EV-302 trial indicate a survival benefit from enfortumab vedotin plus pembrolizumab versus chemotherapy in metastatic urothelial carcinoma. We discuss several key points regarding post-protocol therapies, extending the duration of therapy, toxicity, and costs, all of which may have a bearing on how physicians and patients balance the benefit against the potential harms associated with this regimen.
Texto completo:
1
Coleções:
01-internacional
Temas:
Cuidados_paliativos
/
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Carcinoma de Células de Transição
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Anticorpos Monoclonais Humanizados
/
Anticorpos Monoclonais
Limite:
Humans
Idioma:
En
Revista:
Eur Urol Oncol
Ano de publicação:
2024
Tipo de documento:
Article